Using an NMD inhibitor, cycloheximide, the degradation of the TDP43 V2 isoform was significantly inhibited, confirming the existence of NMD of the TDP43 V2 isoform in breast cancer cells (Fig. 5E). Here, TARDBP is linked to breast cancer.